Zusduri: Revolutionizing Bladder Cancer Treatment Through Targeted Local Delivery
Zusduri is the first FDA-approved targeted, non-surgical treatment for recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. It delivers mitomycin C directly into the bladder using RTGel® technology, which turns from liquid to gel at body temperature. This allows the drug to stay in contact with the bladder wall for hours, maximizing local effect while minimizing […]
Zusduri: Revolutionizing Bladder Cancer Treatment Through Targeted Local Delivery Read More »
